WuXi BioLogics heads to Hong Kong for $300m IPO

china wuxi px230
By Jonathan Breen
05 Jan 2017

China’s WuXi BioLogics is looking south of the border to Hong Kong to go public, preparing an IPO that could raise $300m, according to a banker close to the deal.

The issuer, a subsidiary of Chinese research and development firm WuXi PharmaTech, filed a draft prospectus with the Hong Kong Stock Exchange (HKEX) on Wednesday.

WuXi Biologics is on track to launch its IPO in the second quarter this year and is likely to raise $200m-$300m, said the ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial